SWOG/NRG Joint Study: Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive

PI: Frank A. Vicini


  • Bladder Cancer


Michigan: Maria Pappas (248) 553-0606


  • Bladder cancer

Primary Objective:
To compare bladder intact event-free survival (BI-EFS) for concurrent chemoradiation therapy (CRT) with and without atezolizumab in localized muscle invasive bladder cancer (MIBC).

Patient Population:
Patients with muscle invasive bladder cancer (MIBC) (T2-T4aN0M0).